{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:49:40Z","timestamp":1793342980432,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["UM1 AI068614"],"award-info":[{"award-number":["UM1 AI068614"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029382","name":"HIV Vaccine Trials Network","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100029382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068614"],"award-info":[{"award-number":["UM1 AI068614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128487","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:36:10Z","timestamp":1774078570000},"page":"128487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein"],"prefix":"10.1016","volume":"79","author":[{"given":"Stephen C.","family":"De Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie M.","family":"Gravett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William O.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Villaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorel","family":"Schmitzberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Domin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Heptinstall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ozorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"van der Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Polakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Van","family":"Tieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros A.","family":"Kalams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Marie G.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Purwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Juliana","family":"McElrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128487_bb0005","unstructured":"UNAIDS. Global HIV and AIDS statistics\u2014fact sheet. 2023 [cited 2025 January 26]; Available from: www.unaids.org\/en\/resources\/fact-sheet."},{"issue":"7","key":"10.1016\/j.vaccine.2026.128487_bb0010","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2468-2667(21)00112-2","article-title":"HIV pre-exposure prophylaxis: scaling up for impact now and in the future","volume":"6","author":"Bavinton","year":"2021","journal-title":"Lancet Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128487_bb0015","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1080\/21645515.2020.1823778","article-title":"Durability of response to VGX-3100 treatment of HPV16\/18 positive cervical HSIL","volume":"17","author":"Bhuyan","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128487_bb0020","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137079","article-title":"Robust antibody and cellular responses induced by DNA-only vaccination for HIV","volume":"5","author":"De Rosa","year":"2020","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128487_bb0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"Kalams","year":"2013","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128487_bb0030","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128487_bb0035","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and immunogenicity of an anti-zika virus DNA vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128487_bb0040","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1038\/s41591-025-03969-0","article-title":"Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial","volume":"31","author":"Tebas","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128487_bb0045","article-title":"Use of a novel enhanced DNA vaccine vector for preclinical virus vaccine investigation","volume":"7","author":"Chapman","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128487_bb0050","article-title":"Intramuscular and intradermal electroporation of HIV-1 PENNVAX-GP((R)) DNA vaccine and IL-12 is safe, tolerable, acceptable in healthy adults","volume":"8","author":"Edupuganti","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128487_bb0055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128487_bb0060","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1084\/jem.20161160","article-title":"Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo","volume":"214","author":"Medina-Ramirez","year":"2017","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128487_bb0065","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240604","article-title":"Use of 3M-052-AF with alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies","volume":"221","author":"Hahn","year":"2024","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128487_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128487_bb0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.immuni.2016.08.016","article-title":"HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies","volume":"45","author":"Steichen","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128487_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101477","article-title":"Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (trimer 4571) vaccine in healthy adults: a first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial","volume":"48","author":"Houser","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128487_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112755","article-title":"HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide","volume":"42","author":"Wang","year":"2023","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128487_bb0090","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1128\/JVI.79.12.7933-7937.2005","article-title":"Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1","volume":"79","author":"Wang","year":"2005","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128487_bb0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41467-022-28363-z","article-title":"Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer","volume":"13","author":"Xu","year":"2022","journal-title":"Nat Commun"},{"issue":"6623","key":"10.1016\/j.vaccine.2026.128487_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/science.add6502","article-title":"Vaccination induces HIV broadly neutralizing antibody precursors in humans","volume":"378","author":"Leggat","year":"2022","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128487_bb0105","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128487_bb0110","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01843-17","article-title":"HIV-1 envelope glycoproteins from diverse clades differentiate antibody responses and durability among vaccinees","volume":"92","author":"Yates","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128487_bb0115","series-title":"HIV Protocols","first-page":"395","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","author":"Montefiori","year":"2009"},{"key":"10.1016\/j.vaccine.2026.128487_bb0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2026.128487_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02741","article-title":"Vaccine-induced antibodies mediate higher antibody-dependent cellular cytotoxicity after Interleukin-15 Pretreatment of natural killer effector cells","volume":"10","author":"Fisher","year":"2019","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128487_bb0130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cyto.a.21084","article-title":"High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses","volume":"79","author":"Pollara","year":"2011","journal-title":"Cytometry A"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128487_bb0135","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1128\/JVI.73.11.8966-8974.1999","article-title":"A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor","volume":"73","author":"Trkola","year":"1999","journal-title":"J Virol"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128487_bb0140","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1042\/BCJ20210708","article-title":"New tools for automated cryo-EM single-particle analysis in RELION-4.0","volume":"478","author":"Kimanius","year":"2021","journal-title":"Biochem J"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128487_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128487_bb0150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.immuni.2018.07.009","article-title":"Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization","volume":"49","author":"Bianchi","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128487_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102476","article-title":"Protocol for analyzing antibody responses to glycoprotein antigens using electron-microscopy-based polyclonal epitope mapping","volume":"4","author":"Turner","year":"2023","journal-title":"STAR Protoc"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128487_bb0160","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128487_bb0165","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/cyto.a.22218","article-title":"OMIP-014: validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining","volume":"81","author":"De Rosa","year":"2012","journal-title":"Cytometry A"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128487_bb0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination","volume":"323","author":"Horton","year":"2007","journal-title":"J Immunol Methods"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128487_bb0175","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1128\/JVI.00794-06","article-title":"Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection","volume":"80","author":"Horton","year":"2006","journal-title":"J Virol"},{"issue":"809","key":"10.1016\/j.vaccine.2026.128487_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ady6831","article-title":"Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial","volume":"17","author":"Parks","year":"2025","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128487_bb0185","first-page":"119","article-title":"Approximate is better than \u201cexact\u201d for interval estimation of binomial proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2026.128487_bb0190","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128487_bb0195","unstructured":"SAS Institute Inc., SAS Version 9.4. 2023: Cary, NC, USA."},{"issue":"4","key":"10.1016\/j.vaccine.2026.128487_bb0200","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.immuni.2013.08.031","article-title":"Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses","volume":"39","author":"Locci","year":"2013","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128487_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1129","article-title":"Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination","volume":"9","author":"Huber","year":"2020","journal-title":"Clinical & Translational Immunology"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128487_bb0210","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41590-024-01926-6","article-title":"Influenza vaccination stimulates maturation of the human T follicular helper cell response","volume":"25","author":"Schattgen","year":"2024","journal-title":"Nat Immunol"},{"issue":"519","key":"10.1016\/j.vaccine.2026.128487_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1673","article-title":"Antigenic competition in CD4(+) T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial","volume":"11","author":"Kallas","year":"2019","journal-title":"Sci Transl Med"},{"issue":"6439","key":"10.1016\/j.vaccine.2026.128487_bb0220","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1126\/science.aav5095","article-title":"Structural topology defines protective CD8(+) T cell epitopes in the HIV proteome","volume":"364","author":"Gaiha","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128487_bb0225","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128487_bb0230","article-title":"Deep Mining of the Human Antibody Repertoire Identifies Frequent and Genetically Diverse CDRH3 Topologies Targetable by Vaccination","author":"Habib","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2026.128487_bb0235","doi-asserted-by":"crossref","unstructured":"Dvorscek, A.R., et al., Conversion of vaccines from low to high immunogenicity by antibodies with epitope complementarity. Immunity, 2024. 57(10): p. 2433\u20132452 e7.","DOI":"10.1016\/j.immuni.2024.08.017"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128487_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185666","article-title":"Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza a strains","volume":"12","author":"Nunez","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128487_bib251","doi-asserted-by":"crossref","first-page":"104271","DOI":"10.1016\/j.ebiom.2022.104271","article-title":"Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens","volume":"84","author":"Huang","year":"2022","journal-title":"EBioMedicine"},{"issue":"7945","key":"10.1016\/j.vaccine.2026.128487_bb0245","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41586-022-05609-w","article-title":"Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination","volume":"613","author":"Schaefer-Babajew","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128487_bb0250","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2019.06.010","article-title":"The effect of maternal immunisation during pregnancy on infant vaccine responses","volume":"13","author":"Zimmermann","year":"2019","journal-title":"EClinicalMedicine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:53:08Z","timestamp":1781308388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"alternative-id":["S0264410X26002951"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128487","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128487"}}